These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35203827)

  • 1. High Activity of N-Acetylcysteine in Combination with Beta-Lactams against Carbapenem-Resistant
    De Angelis M; Mascellino MT; Miele MC; Al Ismail D; Colone M; Stringaro A; Vullo V; Venditti M; Mastroianni CM; Oliva A
    Antibiotics (Basel); 2022 Feb; 11(2):. PubMed ID: 35203827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of
    Oliva A; Bianchi A; Russo A; Ceccarelli G; Cancelli F; Aloj F; Alunni Fegatelli D; Mastroianni CM; Venditti M
    Antibiotics (Basel); 2021 Mar; 10(3):. PubMed ID: 33800296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semi-mechanistic PK/PD modelling of meropenem and sulbactam combination against carbapenem-resistant strains of Acinetobacter baumannii.
    Mohd Sazlly Lim S; Heffernan AJ; Zowawi HM; Roberts JA; Sime FB
    Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1943-1952. PubMed ID: 33884516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates].
    Turk Dagi H; Kus H; Arslan U; Tuncer I
    Mikrobiyol Bul; 2014 Apr; 48(2):311-5. PubMed ID: 24819268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bulgecin A as a β-lactam enhancer for carbapenem-resistant
    Skalweit MJ; Li M
    Drug Des Devel Ther; 2016; 10():3013-3020. PubMed ID: 27703329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
    Zhao C; Xie W; Zhang W; Ye Z; Wu H
    Zhonghua Shao Shang Za Zhi; 2014 Apr; 30(2):166-70. PubMed ID: 24989663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology and infection control of carbapenem resistant Acinetobacter baumannii and Klebsiella pneumoniae at a German university hospital: a retrospective study of 5 years (2015-2019).
    Chhatwal P; Ebadi E; Schwab F; Ziesing S; Vonberg RP; Simon N; Gerbel S; Schlüter D; Bange FC; Baier C
    BMC Infect Dis; 2021 Nov; 21(1):1196. PubMed ID: 34837973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibacterial activity of epigallocatechin-3-gallate (EGCG) and its synergism with β-lactam antibiotics sensitizing carbapenem-associated multidrug resistant clinical isolates of Acinetobacter baumannii.
    Lee S; Razqan GS; Kwon DH
    Phytomedicine; 2017 Jan; 24():49-55. PubMed ID: 28160861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minocycline Alone and in Combination with Polymyxin B, Meropenem, and Sulbactam against Carbapenem-Susceptible and -Resistant Acinetobacter baumannii in an
    Beganovic M; Daffinee KE; Luther MK; LaPlante KL
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318006
    [No Abstract]   [Full Text] [Related]  

  • 10. In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
    Oliva A; Scorzolini L; Cipolla A; Mascellino MT; Cancelli F; Castaldi D; D'Abramo A; D'Agostino C; Russo G; Ciardi MR; Mastroianni CM; Vullo V
    J Antimicrob Chemother; 2017 Jul; 72(7):1981-1984. PubMed ID: 28369424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibacterial activity of exogenous glutathione and its synergism on antibiotics sensitize carbapenem-associated multidrug resistant clinical isolates of Acinetobacter baumannii.
    Alharbe R; Almansour A; Kwon DH
    Int J Med Microbiol; 2017 Oct; 307(7):409-414. PubMed ID: 28781060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
    Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
    Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of synergy between sulbactam, meropenem and colistin in carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii isolates and correlation with the molecular mechanism of resistance.
    Laishram S; Anandan S; Devi BY; Elakkiya M; Priyanka B; Bhuvaneshwari T; Peter JV; Subramani K; Balaji V
    J Chemother; 2016 Aug; 28(4):297-303. PubMed ID: 27461479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bactericidal and synergistic activity of double-carbapenem regimen for infections caused by carbapenemase-producing Klebsiella pneumoniae.
    Oliva A; Gizzi F; Mascellino MT; Cipolla A; D'Abramo A; D'Agostino C; Trinchieri V; Russo G; Tierno F; Iannetta M; Mastroianni CM; Vullo V
    Clin Microbiol Infect; 2016 Feb; 22(2):147-153. PubMed ID: 26409059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria.
    Wang Y; Li Y; Zhao J; Guan J; Ni W; Gao Z
    Ann Transl Med; 2022 Mar; 10(5):261. PubMed ID: 35402576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced bacterial killing with colistin/sulbactam combination against carbapenem-resistant Acinetobacter baumannii.
    Bian X; Liu X; Feng M; Bergen PJ; Li J; Chen Y; Zheng H; Song S; Zhang J
    Int J Antimicrob Agents; 2021 Feb; 57(2):106271. PubMed ID: 33352235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-Vitro Evaluation of Different Antimicrobial Combinations with and without Colistin Against Carbapenem-Resistant
    Oliva A; Garzoli S; De Angelis M; Marzuillo C; Vullo V; Mastroianni CM; Ragno R
    Molecules; 2019 Mar; 24(5):. PubMed ID: 30832412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-polymyxin-based combinations as potential alternatives in treatment against carbapenem-resistant Acinetobacter baumannii infections.
    Mohd Sazlly Lim S; Naicker S; Ayfan AK; Zowawi H; Roberts JA; Sime FB
    Int J Antimicrob Agents; 2020 Oct; 56(4):106115. PubMed ID: 32721600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of skin and soft tissue infection due to carbapenem-resistant Acinetobacter baumannii by ampicillin-sulbactam and meropenem combination therapy.
    Hiraki Y; Yoshida M; Masuda Y; Inoue D; Tsuji Y; Kamimura H; Karube Y; Takaki K; Kawano F
    Int J Infect Dis; 2013 Dec; 17(12):e1234-6. PubMed ID: 23791858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of
    Zhang W; Guo Y; Yang Y; Dong D; Zheng Y; Zhu D; Hu F
    Microb Drug Resist; 2020 Mar; 26(3):204-210. PubMed ID: 31553260
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.